Claims:

[Claim 1]. A T Cell Receptor (TCR), optionally isolated, comprising:

a TCR α-chain variable region comprising a CDR3a having the amino acid sequence:

CDR3a: AETLDNYGQNFV (SEQ ID NO:3),;

and

a TCR β-chain variable region comprising a CDR3b having the amino acid sequence:

CDR3b: SAVDRDEPFHSNQPQH (SEQ ID NO:6).

[Claim 2]. A T Cell Receptor (TCR), optionally isolated, comprising:

a TCR α-chain variable region comprising CDRs having the amino acid sequences i) to iii):

i) CDR1a: DXSSTY (SEQ ID NO:1);

ii) CDR2a: IFSNMDM (SEQ ID NO:2);

iii) CDR3a: AETLDNYGQNFV (SEQ ID NO:3);

where X = S or I.

[Claim 3]. A T Cell Receptor (TCR), optionally isolated, comprising:

a TCR β-chain variable region comprising CDRs having the amino acid sequences iv) to vi):

iv) CDR1b: DFQATT (SEQ ID NO:4);

v) CDR2b: SNEGSKA (SEQ ID NO:5);

vi) CDR3b: SAVDRDEPFHSNQPQH (SEQ ID NO:6);

.

[Claim 4]. The TCR according to claim 1, comprising:

a TCR α-chain variable region comprising CDRs having the amino acid sequences i) to iii):

i) CDR1a: DXSSTY (SEQ ID NO:1);

ii) CDR2a: IFSNMDM (SEQ ID NO:2);

iii) CDR3a: AETLDNYGQNFV (SEQ ID NO:3);

and

a TCR β-chain variable region comprising CDRs having the amino acid sequences iv) to vi):

iv) CDR1b: DFQATT (SEQ ID NO:4);

v) CDR2b: SNEGSKA (SEQ ID NO:5);

vi) CDR3b: SAVDRDEPFHSNQPQH (SEQ ID NO:6);

where X = S or I.

[Claim 5]. The TCR according to any one of claims 1 to 4, which is capable of binding to a peptide of a Hepatitis B Virus (HBV) Env polypeptide presented by an MHC class I molecule comprising an MHC class I α-chain encoded by an HLA-Cw*08 allele.

[Claim 6]. The TCR according to claim 5, wherein the peptide comprises positions 171-180 of HBV Env polypeptide.

[Claim 7]. The TCR according to claim 5 or 6, wherein the peptide comprises or consists of the amino acid sequence FLGPLLVLQA (SEQ ID NO:19) or LLGPLLVLQA (SEQ ID NO:20).

[Claim 8]. The TCR according to any one of claims 5 to 7, wherein the HLA-Cw*08 allele is HLA-Cw*0801.

[Claim 9]. The TCR according to any one of claims 5 to 7, wherein the HLA-Cw*08 allele is not HLA-Cw*0801.

[Claim 10]. An isolated nucleic acid encoding a TCR according to any one of claims 1 to 9.

[Claim 11]. The isolated nucleic acid according to claim 10, wherein the nucleic acid comprises:

(a) a nucleic acid sequence encoding a TCR α-chain comprising a variable region and a constant region;

(b) a nucleic acid sequence encoding a TCR β-chain comprising a variable region and a constant region; and

(c) a nucleic acid sequence encoding a cleavable linker;

wherein sequence (c) is located in the isolated nucleic acid between sequences (a) and (b), and wherein sequences (a), (b) and (c) are in the same reading frame.

[Claim 12]. The isolated nucleic acid according to claim 11, wherein sequences (a), (b) and (c) are provided with the 5’ to 3’ orientation: 5’-(b)-(c)-(a)-3’.

[Claim 13]. The isolated nucleic acid according to claim 11 or claim 12, wherein the cleavable linker is a Picornavirus 2A (P2A) linker.

[Claim 14]. The isolated nucleic acid according to any one of claims 11 to 13, wherein the constant region of the TCR α-chain and/or the constant region of the TCR β-chain additionally encode at least one non-native cysteine residue for forming a disulphide bond between the TCR α-chain and TCR β-chain.

[Claim 15]. A vector comprising the isolated nucleic acid according to any one of claims 10 to 14, wherein the vector is selected from a group consists of plasmids, binary vectors, DNA vectors, mRNA vectors, retrovial vectors, lentiviral vectors, transposon-based vectors, and artificial chromosomes.

[Claim 16]. An isolated polypeptide encoded by the isolated nucleic acid according to any one of claims 10 to 14 or the vector of claim 15.

[Claim 17]. An isolated TCR α-chain variable region polypeptide, comprising CDRs having the amino acid sequences i) to iii):

i) CDR1a:	DXSSTY	(SEQ ID NO:1);
ii) CDR2a:	IFSNMDM	(SEQ ID NO:2);
iii) CDR3a:	AETLDNYGQNFV	(SEQ ID NO:3);

where X = S or I.

[Claim 18]. An isolated TCR β-chain variable region polypeptide comprising CDRs having the amino acid sequences iv) to vi):

iv) CDR1b:	DFQATT	(SEQ ID NO:4);
v) CDR2b:	SNEGSKA	(SEQ ID NO:5);
vi) CDR3b:	SAVDRDEPFHSNQPQH	(SEQ ID NO:6);

.

[Claim 19]. A cell, optionally isolated, comprising the TCR according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector of claim 15 or the isolated polypeptide of any one of claims 16 to 18.

[Claim 20]. The cell according to claim 19, wherein the cell displays one or more of the following properties:

a) expression of IFNγ;

b) cytotoxicity to a cell infected with HBV or comprising or expressing an HBV Env peptide or polypeptide;

c) proliferation, increased IFNγ expression, increased IL-2 expression, increased TNFα expression, increased perforin expression, increased granzyme expression and/or increased FAS ligand (FASL) expression in response to contact with a cell infected with HBV or comprising or expressing an HBV Env peptide or polypeptide;

[Claim 21]. An *in vitro* method of producing a Hepatitis B Virus (HBV) reactive T cell, comprising introducing into a cell the isolated nucleic acid according to any one of claims 10 to 14, or the vector according to claim 15.

[Claim 22]. The method of claim 21, wherein the method additionally comprises culturing the cell under conditions suitable for expression of the isolated nucleic acid or vector by the cell.

[Claim 23]. A cell, optionally isolated, wherein the cell is obtained or obtainable by the method of claim 21 or claim 22.

[Claim 24]. A complex, optionally an *in vitro* complex, comprising the TCR according to any one of claims 1 to 9, a polypeptide according to any one of claims 16 to 18, or a cell according to any one of claims 19, 20 or claim 23 and a Hepatitis B Virus (HBV) Env peptide or polypeptide, optionally further comprising an MHC class I molecule comprising an MHC class I α-chain encoded by an HLA-Cw*08 allele.

[Claim 25]. A pharmaceutical composition comprising a TCR according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector according to claim 15, the isolated polypeptide according to any one of claims 16 to 18, or the cell according to any one of claims 19, 20 or claim 23, and a pharmaceutically acceptable carrier, adjuvant, excipient, or diluent.

[Claim 26]. The TCR according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector according to claim 15, the isolated polypeptide according to any one of claims 16 to 18, the cell according to any one of claims

19, 20 or claim 23, or the pharmaceutical composition of claim 25 for use in a method of treating or preventing a disease or disorder.

[Claim 27]. Use of the TCR according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector according to claim 15, the isolated polypeptide according to any one of claims 16 to 18, the cell according to any one of claims 19, 20 or claim 23, or the pharmaceutical composition of claim 25 in the manufacture of a medicament for treating or preventing a disease or disorder wherein the disease or disorder is caused or exacerbated by Hepatitis B Virus (HBV) infection, or a disease or disorder for which HBV infection is a risk factor.

[Claim 28]. The TCR, isolated nucleic acid, vector, isolated polypeptide, cell or pharmaceutical composition for use according to claim 26, wherein the disease or disorder is caused or exacerbated by Hepatitis B Virus (HBV) infection, or a disease or disorder for which HBV infection is a risk factor.

[Claim 29]. The TCR, isolated nucleic acid, vector, isolated polypeptide, cell or pharmaceutical composition for use according to claim 26 or 28, wherein the disease is one or more of hepatitis B, hepatocellular carcinoma or pancreatic cancer.

[Claim 30]. The TCR, isolated nucleic acid, vector, isolated polypeptide, cell or pharmaceutical composition for use according to claim 26, 28 or 29, wherein the subject to be treated has an HLA-C genotype comprising an HLA-Cw*08 allele.

[Claim 31]. The TCR, isolated nucleic acid, vector, isolated polypeptide, cell or pharmaceutical composition for use according to claim 30, wherein the HLA-Cw*08 allele is HLA-Cw*0801.

[Claim 32]. The TCR, isolated nucleic acid, vector, isolated polypeptide, cell or pharmaceutical composition for use according to claim 30, wherein the HLA-Cw*08 allele is not HLA-Cw*0801.

[Claim 33]. The TCR, isolated nucleic acid, vector, isolated polypeptide, cell or pharmaceutical composition for use according to claim 26 or claims 28 to 32, wherein the subject is infected with, or wherein the subject is at risk of infection by, Hepatitis B Virus (HBV).

[Claim 34]. The TCR, isolated nucleic acid, vector, isolated polypeptide or cell for use according to claim 33, wherein the HBV is selected from HBV genotype A, B, C, D, E, F, G, H, I or J.

[Claim 35]. An *in vitro* method for preparing a modified T cell, the method comprising introducing into a T cell the TCR according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector according to claim 15, or the isolated polypeptide according to any one of claims 16 to 18.

[Claim 36]. A method of identifying a subject for therapeutic or prophylactic treatment of a disease or disorder using the TCR or fragment according to any one of claims 1 to 10, the isolated nucleic acid according to any one of claims 11 to 15, the vector according to claim 16, the isolated polypeptide according to any one of claims 17 to 19, the cell according to any one of claims 20 to 22 or claim 25, or the pharmaceutical composition of claim 27, the method comprising determining the HLA-C genotypein a sample obtained from a subject, wherein a sample obtained from a subject determined to have an HLA-Cw*08 allele is identified as being a subject suitable for therapeutic or prophylactic treatment.

[Claim 37]. The method according to claim 36, wherein the HLA-Cw*08 allele is HLA-Cw*0801.

[Claim 38]. The method according to claim 36, wherein the HLA-Cw*08 allele is not HLA-Cw*0801.

[Claim 39]. A method of identifying a subject for therapeutic or prophylactic treatment of a disease or disorder using the TCR or fragment according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector according to claim 15, the isolated polypeptide according to any one of claims 16 to 18 the cell according to any one of claims 19 to 20 or claim 23, or the pharmaceutical composition of claim 25, the method comprising determining whether the subject is infected with, or determining whether the subject is at risk of infection by, Hepatitis B Virus (HBV).

[Claim 40]. The method according to claim 39, wherein the HBV is selected from HBV genotype A, B, C, D, E, F, G, H, I or J.

[Claim 41]. A method for diagnosing Hepatitis B Virus (HBV) infection in a subject, the method comprising detecting in a sample obtained from a subject, optionally *in vitro*, the presence of the TCR according to any one of claims 1 to 10, the complex according to claim 26, the isolated nucleic acid according to any one of claims 11 to 15, the vector according to claim 16, the isolated polypeptide according to any one of claims 17 to 19, or the cell according to any one of claims 20 to 22 or claim 25.

[Claim 42]. The method according to claim 41, wherein the HBV is selected from HBV genotype A, B, C, D, E, F, G, H, I or J.

[Claim 43]. The method according to claim 41 or 42, wherein the subject has an HLA-Cw*08 allele.

[Claim 44]. The method according to claim 43, wherein the HLA-Cw*08 allele is HLA-Cw*0801.

[Claim 45]. The method according to claim 43, wherein the HLA-Cw*08 allele is not HLA-Cw*0801.

[Claim 46]. A kit of parts comprising a predetermined quantity of the TCR according to any one of claims 1 to 9, the isolated nucleic acid according to any one of claims 10 to 14, the vector according to claim 15, the isolated polypeptide according to any one of claims 16 to 18 the cell according to any one of claims 19 to 20 or claim 23, or the pharmaceutical composition of claim 25.